Correlation of HER2 gene and chromosome 17 status with pathologic factors in her2 2+ invasive breast cancer

被引：0
|
作者：
MacGrogan, G. [1 ]
Chibon, F. [1 ]
de Mascarel, I. [1 ]
Sierankowski, G. [1 ]
Brouste, V. [1 ]
机构：
[1] Inst Bergonie, Bordeaux, France
来源：
LABORATORY INVESTIGATION | 2007年 / 87卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
162
引用
收藏
页码：40A / 40A
页数：1
相关论文
共 50 条
  • [41] Prediction of HER2 gene status in Her2 2+invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations
    Chibon, Frederic
    de Mascarel, Isabelle
    Sierankowski, Ghislaine
    Brouste, Veronique
    Bonnefoi, Herve
    Debled, Marc
    Mauriac, Louis
    MacGrogan, Gaetan
    MODERN PATHOLOGY, 2009, 22 (03) : 403 - 409
  • [42] Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification
    Lee, Andrew H. S.
    Key, Heather P.
    Bell, Jane A.
    Hodi, Zsolt
    Ellis, Ian O.
    JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (06) : 490 - 492
  • [43] Correction for chromosome 17 is critical for determination of true Her2 gene amplification status in breast cancer (BC)
    Larsimont, D
    Durbecq, V
    Desmedt, C
    Salgado, R
    Dal Lago, L
    Lespagnard, L
    Verjat, T
    Sotiriou, C
    LABORATORY INVESTIGATION, 2006, 86 : 32A - 32A
  • [44] Correction for chromosome 17 is critical for determination of true HER2 gene amplification status in breast cancer (BC)
    Larsimont, D
    Durbecq, V
    Desmedt, C
    Salgado, R
    Dal Lago, L
    Lespagnard, L
    Verjat, T
    Sotiriou, C
    MODERN PATHOLOGY, 2006, 19 : 32A - 32A
  • [45] Cytogenetic Alterations in Her2/Neu Gene (HER2) and Chromosome 17 (chr17) by Fluorescent In-Situ Hybridization (FISH) in Immunohistochemically (IHC) Equivocal (2+) Breast Cancers
    Chitale, D. A.
    Sanchez, J.
    Adeyinka, A.
    LABORATORY INVESTIGATION, 2011, 91 : 32A - 32A
  • [46] Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancer
    Egervari, Kristof
    Kosa, Csaba
    Szollosi, Zoltan
    PATHOLOGY RESEARCH AND PRACTICE, 2011, 207 (08) : 468 - 471
  • [47] HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study
    Halilovic, Altuna
    Verweij, Dagmar, I
    Simons, Annet
    Stevens-Kroef, Marian J. P. L.
    Vermeulen, Susan
    Elsink, Janet
    Tops, Bastiaan B. J.
    Otte-Holler, Irene
    van der Laak, Jeroen A. W. M.
    van de Water, Carlijn
    Boelens, Oliver B. A.
    Schlooz-Vries, Margrethe S.
    Dijkstra, Jeroen R.
    Nagtegaal, Iris D.
    Tol, Jolien
    van Cleef, Patricia H. J.
    Span, Paul N.
    Bult, Peter
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [48] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [49] HER2 Gene Protein Assay Is Useful to Determine HER2 Status of Breast Carcinoma with HER2 IHC and FISH Double Equivocal Results
    Li, Zaibo
    Hou, Yanjun
    Nitta, Hiroaki
    MODERN PATHOLOGY, 2016, 29 : 54A - 54A
  • [50] Correlation of immunohistochemistry-equivocal (2+) human epidermal growth factor receptor 2 (HER2) with fluorescence in situ hybridization (FISH) gene status in invasive breast cancer: Is FISH necessary for all HER2 equivocal breast cancer cases?
    Alswayyed, Mohammed
    KUWAIT MEDICAL JOURNAL, 2022, 54 (04): : 476 - 480
12345